UOBKayHian

技術分析 | 大中華

Thursday, 12 November 2026

技術分析

分析師

大中華區研究團隊
research-hk@uobkh.com

譚文漢，特許財務分析師
munhon.tham@uobkh.com
+852 2236 6799



中信股份 (0267 HK)

最後價格:	港幣 12.94 元
支撐位:	港幣 12.49 元/港幣 12.10 元
阻力位:	港幣 13.70 元/港幣 14.57 元

技術分析:

价格行为在突破后展开了高确信度的结构性防守，成功守住了缺口支撑基线上方的位置，并构筑了一个看涨旗形趋势延续形态。RSI 指标牢牢锚定于看涨区间，并继续以正向速度向上斜升。一旦价格坚决突破旗形形态，预期将展开向上突破浪潮，目标指向更高的波段高点阻力边界与主要测量目标扩展界限。

平均時限：約兩週。



信達生物 (1801 HK)

最後價格:	港幣 86.80 元
支撐位:	港幣 84.40 元/港幣 77.90 元
阻力位:	港幣 98.95 元/港幣 103.50 元

技術分析:

价格行为在盘中回踩中成功守住了突破缺口支撑基线上方的位置，并在一个紧凑的区间内展开收敛盘整。RSI 指标盘旋于 50 中性基线附近。在结构性极性防守的框架下，只要价格行为严格防守在缺口支撑基线上方，最小阻力路径将高度倾斜于展开向上拓展浪潮，目标指向更高的波段高点阻力区域。

平均時限：約兩週。

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at this link or by scanning the QR code below:

The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."